AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14528134 — intervention group
Group type: COMPARATOR
Intervention: Telephonic disease management
Number of subjects: 90
Study 14528134 — intervention group
Group type: COMPARATOR
Intervention: Traditional home management strategies (telephonic, home visit)
Number of subjects: 90
Study 10751262 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-medicated patients with advanced PD
Number of subjects: 48
Study 10751262 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated patients with early PD
Number of subjects: 48
Study 10751262 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 48
Study 9216152 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural classifier using flow cytometry data
Number of subjects: 170
Study 1358004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.50 mg.kg‐1
Number of subjects: 56
Study 1358004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.10 mg.kg‐1
Number of subjects: 56
Study 1358004 — intervention group
Group type: COMPARATOR
Intervention: Control (no tetanic stimulation)
Number of subjects: 56
Study 3877288 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 12
Study 3877288 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 12
Study 31980826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 24
Study 29368802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice (BRJ) containing 12.3 ± 0.8 mmol of NO3‐
Number of subjects: 20
Study 29368802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beetroot juice devoid of NO3‐)
Number of subjects: 20
Study 27515333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 473
Study 27515333 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 473
Study 25258045 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and exercise interventions
Number of subjects: 222
Study 22897617 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous noncultured epidermal cell suspension (NCES)
Number of subjects: 41
Study 22897617 — intervention group
Group type: COMPARATOR
Intervention: Suction blister epidermal grafting (SBEG)
Number of subjects: 41
Study 22897617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NCES and SBEG
Number of subjects: 41
Study 20618316 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis by the Omniview‐SisPorto 3.5 system (study group n = 104)
Number of subjects: 204
Study 20618316 — intervention group
Group type: COMPARATOR
Intervention: No analysis (control group n = 100)
Number of subjects: 204
Study 18346604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% + morphine
Number of subjects: 18
Study 18346604 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% + morphine
Number of subjects: 18
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesilate (Gleevec) for metastatic gastrointestinal stromal tumors (GISTs)
Number of subjects: 0
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa) for esophageal and colorectal cancer
Number of subjects: 0
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva) for esophageal, colorectal, hepatocellular, biliary carcinoma, and pancreatic cancer
Number of subjects: 0
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) for irinotecan resistant colorectal cancer
Number of subjects: 0
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) for metastatic colorectal cancer
Number of subjects: 0
Study 15892618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) in combination with gemcitabine for pancreatic cancer
Number of subjects: 0
Study 12009370 — intervention group
Group type: EXPERIMENTAL
Intervention: One transcervical insertion of 252 mg of quinacrine
Number of subjects: 100
Study 12009370 — intervention group
Group type: EXPERIMENTAL
Intervention: Two transcervical insertions of 252 mg of quinacrine
Number of subjects: 100
Study 10544425 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 10544425 — intervention group
Group type: COMPARATOR
Intervention: Passive physical education activities
Number of subjects: 0
Study 10544425 — intervention group
Group type: COMPARATOR
Intervention: Directed physical education activities
Number of subjects: 0
Study 7775186 — intervention group
Group type: COMPARATOR
Intervention: 75 mg meperidine with 25 mg promethazine IM
Number of subjects: 27
Study 7775186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dihydroergotamine with 10 mg metoclopramide IV
Number of subjects: 27
Study 2190629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg oral dose
Number of subjects: 12
Study 495064 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith-Petersen osteosynthesis
Number of subjects: 197
Study 495064 — intervention group
Group type: COMPARATOR
Intervention: Sliding-nail-plate osteosynthesis
Number of subjects: 197
Study 30025177 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g of intravenous MgSO4 (low-dose group)
Number of subjects: 450
Study 30025177 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of intravenous MgSO4 (high-dose group)
Number of subjects: 450
Study 30025177 — intervention group
Group type: COMPARATOR
Intervention: Serum saline infusion (placebo group)
Number of subjects: 450
Study 26763665 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (V)
Number of subjects: 60
Study 26763665 — intervention group
Group type: EXPERIMENTAL
Intervention: Superbond (S)
Number of subjects: 60
Study 26763665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (C)
Number of subjects: 60
Study 26763665 — intervention group
Group type: COMPARATOR
Intervention: Control group (young teeth)
Number of subjects: 60
Study 26763665 — intervention group
Group type: COMPARATOR
Intervention: Control group (geriatric teeth)
Number of subjects: 60
Study 27278926 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Beet Juice (RBJ)
Number of subjects: 24
Study 27278926 — intervention group
Group type: COMPARATOR
Intervention: Cooked Beet (CB)
Number of subjects: 24
Study 24848793 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsules containing 200 million of seven strains of friendly bacteria plus fructo‐oligosaccharide, twice a day for 28 weeks
Number of subjects: 38
Study 24848793 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 28 weeks
Number of subjects: 38
Study 24848793 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsules
Number of subjects: 38
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase (500 FTU/kg) with low nonphytate P (0.18%)
Number of subjects: 144
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase (500 FTU/kg) with high calcium (0.77%)
Number of subjects: 144
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium (0.77%) and low nonphytate P (0.18%)
Number of subjects: 144
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium (0.37%) and high nonphytate P (0.32%)
Number of subjects: 144
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium (0.37%)
Number of subjects: 144
Study 23091139 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dietary calcium
Number of subjects: 144
Study 19084376 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched milk (500 mL/d)
Number of subjects: 297
Study 19084376 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk (500 mL/d)
Number of subjects: 297
Study 19084376 — intervention group
Group type: COMPARATOR
Intervention: Semi-skimmed milk (500 mL/d)
Number of subjects: 297
Study 17445067 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 MHz RF exposure (2W)
Number of subjects: 30
Study 17445067 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 MHz RF exposure (1W)
Number of subjects: 30
Study 17445067 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 30
Study 15645325 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor position A (frontal at eye level)
Number of subjects: 18
Study 15645325 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor position B (frontal in height of the operating field)
Number of subjects: 18
Study 15645325 — intervention group
Group type: COMPARATOR
Intervention: Monitor position C (45 degrees to the right side at eye level)
Number of subjects: 18
Study 11990912 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400-mg fluconazole dose
Number of subjects: 109
Study 11990912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9226511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg administered nightly with gonadotropin therapy
Number of subjects: 42
Study 9226511 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin therapy without dexamethasone (control group)
Number of subjects: 42
Study 7960733 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 64
Study 7960733 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 64
Study 2890509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (three times)
Number of subjects: 30
Study 2890509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31017381 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring wheel during the 6MWT
Number of subjects: 317
Study 31017381 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking during the 6MWT
Number of subjects: 317
Study 31017381 — intervention group
Group type: EXPERIMENTAL
Intervention: Students from sports schools
Number of subjects: 317
Study 31017381 — intervention group
Group type: EXPERIMENTAL
Intervention: Height, post-test heart rate, male sex, measuring wheel
Number of subjects: 317
Study 30027281 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) only
Number of subjects: 682
Study 30027281 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC + low-molecular-weight (LMW) heparin sodium
Number of subjects: 682
Study 30027281 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC + LMW heparin sodium
Number of subjects: 682
Study 30027281 — intervention group
Group type: COMPARATOR
Intervention: IPC only
Number of subjects: 682
Study 27838692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapor ablation (BTVA)
Number of subjects: 69
Study 27838692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 24661535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active games intervention for 10 months, including encouragement to play.
Number of subjects: 0
Study 24661535 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group receiving active games after the intervention period.
Number of subjects: 0
Study 24661535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active games intervention
Number of subjects: 0
Study 22178004 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 84
Study 22178004 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate, High Fiber (HCHF) diet
Number of subjects: 84
Study 22178004 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 84
Study 20197322 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 VLP vaccine with AS04 adjuvant (n=13,075)
Number of subjects: 26130
Study 20197322 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control) (n=13,055)
Number of subjects: 26130
Study 19087694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin 5 (TP5) combined with prednisone + pyridostigmine for 3 months
Number of subjects: 135
Study 19087694 — intervention group
Group type: COMPARATOR
Intervention: Prednisone + pyridostigmine for 3 months (non-TP5 group)
Number of subjects: 135
Study 15956124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecadenoson 300 microg/600 microg
Number of subjects: 181
Study 15956124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecadenoson (various doses)
Number of subjects: 181
Study 15956124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15311665 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation instruction (judging each square solely in relation to its own category)
Number of subjects: 0
Study 15311665 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration instruction (ignoring category membership)
Number of subjects: 0
Study 10878628 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol (Visipaque) 320 mg I/ml
Number of subjects: 48
Study 10878628 — intervention group
Group type: COMPARATOR
Intervention: iohexol (Omnipaque) 350 mg I/ml
Number of subjects: 48
Study 9426846 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcijex (1,25(OH)2D3)
Number of subjects: 20
Study 9426846 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable One‐Alpha (1(OH)D3)
Number of subjects: 20
Study 9426846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin D3 (Calcijex and injectable One‐Alpha)
Number of subjects: 20
Study 9426846 — intervention group
Group type: COMPARATOR
Intervention: Oral One‐Alpha
Number of subjects: 20
Study 8262827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 20 fractions
Number of subjects: 71
Study 8262827 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy in 10 fractions
Number of subjects: 71
Study 8262827 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in 1 fraction
Number of subjects: 71
Study 3886399 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY l 5240 (nifedipine 10 mg + acebutolol 100 mg)
Number of subjects: 116
Study 3886399 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg
Number of subjects: 116
Study 2465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with methotrexate (MTX) and 5-fluorouracil (5FU)
Number of subjects: 16
Study 2465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-venous CMFV treatment (in cases with objective remission)
Number of subjects: 16
Study 2465650 — intervention group
Group type: COMPARATOR
Intervention: Systemic FACV combination
Number of subjects: 16
Study 31876292 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of rate-adaptive pacing parameters using cardiopulmonary exercise testing (CPET) and pacemaker stress echocardiography (PASE)
Number of subjects: 54
Study 30092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-to-Music (M2M)
Number of subjects: 81
Study 30092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Yoga (AY)
Number of subjects: 81
Study 30092206 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 81
Study 28056205 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Rehabilitation Program (Insight)
Number of subjects: 242
Study 28056205 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 242
Study 26270586 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg IV dexamethasone
Number of subjects: 160
Study 26270586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24086815 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate silver dressing (AlSD)
Number of subjects: 20
Study 24086815 — intervention group
Group type: COMPARATOR
Intervention: Silver zinc sulfadiazine cream (AgZnSD)
Number of subjects: 20
Study 21256654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic imaging (USI)
Number of subjects: 91
Study 21256654 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 91
Study 19892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 500 mg/m(2)
Number of subjects: 39
Study 19892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 750 mg/m(2)
Number of subjects: 39
Study 19892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 1,000 mg/m(2)
Number of subjects: 39
Study 19892663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 39
Study 19892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline stromal VEGF
Number of subjects: 39
Study 17047645 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter communication of risk information
Number of subjects: 87
Study 17047645 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal interview communication of risk information
Number of subjects: 87
Study 15538094 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide (50 mg/12.5 mg)
Number of subjects: 585
Study 15538094 — intervention group
Group type: COMPARATOR
Intervention: losartan
Number of subjects: 585
Study 10932333 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation
Number of subjects: 16
Study 10932333 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 9306091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free milk (4.9% lactose)
Number of subjects: 30
Study 9306091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milk (8% fat, 4.9% lactose)
Number of subjects: 30
Study 9306091 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free and fat-free control milk
Number of subjects: 30
Study 9306091 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fat-free milk and high-fat milk
Number of subjects: 30
Study 8367786 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion using autogenous bone graft (Group I)
Number of subjects: 124
Study 8367786 — intervention group
Group type: COMPARATOR
Intervention: Autogenous posterolateral fusions supplemented by a semi-rigid pedicle screw/plate fixation system (Group II)
Number of subjects: 124
Study 8367786 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral autogenous fusion with a rigid pedicle screw/rod fixation system (Group III)
Number of subjects: 124
Study 2430180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetrahydroaminoacridine (THA)
Number of subjects: 17
Study 31701317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance of the PVC tip until it penetrates the lumen (group A)
Number of subjects: 300
Study 31701317 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC insertion partially controlled by ultrasound (group B)
Number of subjects: 300
Study 31701317 — intervention group
Group type: COMPARATOR
Intervention: PVC without any ultrasound guidance (group C)
Number of subjects: 300
Study 29033271 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical module
Number of subjects: 30
Study 29033271 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical module (naïve subjects)
Number of subjects: 30
Study 29033271 — intervention group
Group type: COMPARATOR
Intervention: Nonmodule
Number of subjects: 30
Study 27168264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2102
Study 27168264 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2102
Study 25008127 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention (Happy@Work), consisting of 6 lessons of problem-solving treatment and cognitive therapy, with weekly assignments and feedback from a coach.
Number of subjects: 231
Study 25008127 — intervention group
Group type: COMPARATOR
Intervention: Control as usual (CAU)
Number of subjects: 231
Study 22853852 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 60
Study 22853852 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 60
Study 20688462 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of rhTSH IV 24 h before (123)I
Number of subjects: 7
Study 20688462 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of rhTSH IV 48 h before (123)I
Number of subjects: 7
Study 20688462 — intervention group
Group type: COMPARATOR
Intervention: Baseline RAIU with (123)I
Number of subjects: 7
Study 18279973 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) session
Number of subjects: 24
Study 18279973 — intervention group
Group type: COMPARATOR
Intervention: Control group assessment (no ECT session)
Number of subjects: 24
Study 16148718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheotomy (PDT)
Number of subjects: 43
Study 16148718 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheotomy (ST)
Number of subjects: 43
Study 12598344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus leucovorin (arm A)
Number of subjects: 680
Study 12598344 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus levamisole (arm B)
Number of subjects: 680
Study 10322096 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor therapy (four intravenous doses)
Number of subjects: 0
Study 7497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 2 x ED95 (0.150 mg.kg‐1) with priming
Number of subjects: 5
Study 7497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 3 x ED95 (0.215 mg.kg‐1) with priming
Number of subjects: 5
Study 7497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg.kg‐1)
Number of subjects: 5
Study 7497557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 1 x ED95 (0.075 mg.kg‐1) with priming
Number of subjects: 5
Study 7497557 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 2 x ED95 (saline prime)
Number of subjects: 5
Study 1798310 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-second maximum voluntary isometric contraction (MVIC) with SRHR flexibility technique
Number of subjects: 60
Study 1798310 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-second maximum voluntary isometric contraction (MVIC) with SRHR flexibility technique
Number of subjects: 60
Study 1798310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-second maximum voluntary isometric contraction (MVIC) with SRHR flexibility technique
Number of subjects: 60